Anlon Healthcare Q1 FY27 Results (NSE: AHCL)
Signal: Margin pressure
The read
The Q1FY27 filing marks a structural shift: the company is no longer a standalone API manufacturer but a holding company consolidating three subsidiaries. Consolidated revenue of ₹87.56 Cr (+163% YoY) is dominated by subsidiary contributions (₹57.07 Cr), while standalone revenue shrank 7% YoY. Group EBITDA margin compressed to 15.6% (from 19.2% a year ago) as the acquired businesses operate at lower margins. PAT of ₹8.28 Cr was diluted by a 39.4% tax rate and ₹1.62 Cr earmarked for non-controlling interests. The share swap to acquire full ownership of Apiqo Organics and Bizotic Lifescience will eliminate NCI going forward, but the immediate earnings quality issue is the EPS dilution that already occurred—PAT up 133% but EPS up only 78%.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹87.56 Cr | +163.0% | +72.1% |
| EBIT | ₹13.66 Cr | +173.0% | |
| Net profit | ₹8.28 Cr | +133.5% | |
| EPS | ₹0.16 | +77.8% | |
| EBIT margin | 15.6% |
P&L walk
Consolidated revenue nearly tripled YoY to ₹87.56 Cr due to first-time full-quarter consolidation of subsidiaries (Apiqo Organics, Bizotic Lifescience), which contributed ₹57.07 Cr of revenue; EBITDA margin compressed sharply to 15.6% (vs 19.2% in Q1FY26 and 28.4% in Q4FY26) as the subsidiaries carry lower margins than the standalone entity, while PAT grew 133% to ₹8.28 Cr, with ₹1.62 Cr attributable to non-controlling interests.
Key positives
- Consolidated revenue grew 163% YoY to ₹87.56 Cr, driven by full-quarter consolidation of two subsidiaries.
- Consolidated PAT grew 133% YoY to ₹8.28 Cr, with subsidiaries contributing ₹3.48 Cr PAT before consolidation adjustments.
- Standalone gross margin expanded 980bps YoY to 40.1%, on lower raw material costs and inventory destocking.
- Company is pursuing a share swap to acquire full ownership (32.52% and 43.33% remaining) of Apiqo Organics and Bizotic Lifescience, which would make them wholly owned subsidiaries and eliminate non-controlling interest drag.
Key concerns
- Standalone revenue declined 7% YoY to ₹30.98 Cr, indicating organic API business is in a soft patch.
- Consolidated EBITDA margin compressed 360bps YoY to 15.6%, as subsidiaries operate at structurally lower margins than the parent.
- EPS growth (78%) materially lagged PAT growth (133%) due to equity dilution from the share swap/restructuring—paid-up capital doubled to ₹10.63 Cr.
- Non-controlling interests absorbed ₹1.62 Cr (19.6% of group PAT), reducing the stake of parent shareholders in subsidiary profits.
- Effective tax rate on consolidated basis jumped to 39.4% (vs 29.1% in Q1FY26) due to deferred tax provisions in subsidiaries.
Research and educational content only. Not investment advice.